ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
ImmunityBio gets lung cancer boost
But PFS data are lacking, and there are questions about first and second-line plans.
EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
J&J’s bladder hope gets its first approval
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
